Ophthalmic Care News
-
Showcase
Mojo Vision Reaches Significant Development Milestone for Smart Contact Lens
New prototype of Mojo Lens incorporates numerous industry-first features, including the world’s smallest and densest dynamic display, low-latency communication, and an eye-controlled user interface SARATOGA, Calif.--(March 30, 2022)--Mojo Vision, the Invisible Computing Company, today announced its most advanced prototype of Mojo Lens, the world's first true smart contact lens, including ...
-
5 Ways OCT Technology Can Benefit Your Practice
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, the naked eye’s powers are limited. That’s where OCT technology comes in handy. OCTs have become a standard of care that every practice ...
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). If the FDA has no further comments after the 30-day review period, BRIM will proceed to initiate the Phase 3 clinical trial in December. Based on its ...
-
Tank Renovation Rescheduled for 2021
Good news - the Ohmsett tank renovations planned for the summer of 2020 that would have the tank off-line for three months is rescheduled to take place in the summer of 2021. There are now 17 weeks of testing available! Book your project today to lock in your preferred dates. Contact Len Zabilansky at 732-866-7285 or ...
By OHMSETT
-
iSTAR Medical appoints leading glaucoma specialist Prof. Kaweh Mansouri as Chief Medical Officer
WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO). Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, ...
-
MediPrint™ Ophthalmics Announces Acceptance and Presentation of Poster at the Upcoming GSLS in Las Vegas
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results ...
-
Optina Diagnostics Earns Frost & Sullivan’s 2022 NA Technology Innovation Leadership Award
Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the 2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping™ solutions. Optina Diagnostics’ comprehensive technology facilitates early and non-invasive diagnostic ...
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures ...
-
Atia Vision, a Shifamed Portfolio Company, to Close on $42m Series E Financing
CAMPBELL, CA – August 2, 2022 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting intraocular lens (IOL), announced today the first close of a $42M Series E financing. Led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), PA MedTech VC Fund, AMED Ventures ...
-
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
NORTH CHICAGO, Ill. and WAVRE, BELGIUM, July 20, 2022 – AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical’s development ...
-
Turning a Great Idea into a Successful Product: ASPIRE
For VisionQuest’s vice president and principal investigator Vinayak Joshi (PhD), the journey from idea to commercial product has led him halfway around the world. Dr. Joshi recently traveled to Malawi, Kenya, Nigeria, and Ghana as part of his efforts to commercialize ASPIRE, his device for the detection and diagnosis of malarial retinopathy. While in Africa, he met with leaders in ...
-
iSTAR Medical Presents Positive Consistent Results for MINIject Across Three International Glaucoma Trials
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
-
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Datagrafic lines 4 Sight Sciences’ OMNI® Surgical System Redu
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced publication in Clinical Ophthalmology of its 12-month outcomes in the GEMINI study, including results from a Hispanic population subset. The final study results demonstrated that canaloplasty ...
-
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM ...
-
Cerevast Medical Enters Into Strategic Collaboration With Lantheus Medical Imaging for Retinal Vein Occlusion Treatment
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By ...
-
iSTAR Medical Expands Commercial Rollout with First MINIject Surgeries in Switzerland
The only commercially available MIGS device currently targeting the supraciliary space now available to patients and surgeons in Switzerland First implantations performed by Prof. Dr Kaweh Mansouri at Swiss Visio, Clinique de Montchoisi, Lausanne and Prof. Dr med. Jan Darius Unterlauft at Inselspital, Bern WAVRE, Belgium — 10 May 2022: iSTAR Medical, a medtech company delivering ...
-
Alfa Chemistry Introduces Polyquaternium for Cosmetics and Personal Care Products Industry
Emerged as a supplier of quaternary ammonium compounds (QACs), Alfa Chemistry has previously released halide quaternary ammonium salt and acid radical quaternary ammonium salts, and aimed to further enrich its portfolio, the company recently introduces a new polyquaternium product line for customers who are engaged in the cosmetics and personal care products industry. Polyquaternium is a ...
-
MediPrint™ Ophthalmics Announces Initial Series A Funding Success
SAN DIEGO–(BUSINESS WIRE) (March 15th, 2022) –Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors. There will be a subsequent close of this round, in Q2 2022, when the round is ...
-
Digital Diagnostics and Baxter Announce New Partnership
Coralville, Iowa and Deerfield, Ill., March 9, 2022 – Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front line care providers deliver high-quality care and improve care outcomes. The partnership includes plans to offer Digital Diagnostics’ industry-leading IDx-DR® autonomous AI software as a diagnostic service combined with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you